… The present study is the first prospective randomized phase II trial to evaluate clinical … in
patients with NSCLC who have failed prior chemotherapy. To minimize heterogeneity of study …

… one previous platinum-doublet chemotherapy regimen and who were considered candidates
for further chemotherapy. … following previous chemotherapy (adjuvant chemotherapy was …

… Eligible patients had a performance status 0 to 2, previous treatment with one prior
chemotherapy regimen for advanced NSCLC, and adequate organ function. Patients received …

… The observed survival rates exceed those of previous CALGB trials and may be … chemotherapy
added to concomitant chemoradiotherapy is being evaluated in a phase III randomized …

… or younger; no previous malignancies other than superficial skin cancer or in situ cervical
carcinoma; no previous treatments such as neoadjuvant chemotherapy or radiotherapy; and …

… characteristics were balanced, except for the proportion of patients who had received two
previous chemotherapy regimens (Table 1). To further explore prognostic factors for OS, we …

… phase II results of docetaxel monotherapy, this phase III trial was conducted of chemotherapy
… -cell lung cancer (NSCLC) who had previously failed platinum-containing chemotherapy. …

… In a pooled analysis of our previous trials, primary chemotherapy yielded a mean decrease
in Ki-67 of 41%, with a reasonably normal distribution and a standard deviation of 30%. This …

… were similar or even better than those of other phase II or III docetaxel single-drug salvage
chemotherapy studies. At least 34 of our patients received … Randomized phase II clinical trials …

… This randomized phase II–III trial sought to evaluate the efficacy and safety of adding
bevacizumab (Bev) following induction chemotherapy (CT) in extensive small-cell lung cancer (…